Product logins

Find logins to all Clarivate products below.


Multiple Myeloma – Landscape & Forecast – Disease Landscape & Forecast (G7)

Treatment of multiple myeloma is complex. It involves a combination of proteasome inhibitors and/or immunomodulatory drugs (IMiDs) with chemotherapy. Treatment may also include cell-surface-targeted agents (e.g., Johnson & Johnson Innovative Medicine’s Darzalex) or other chemotherapy-based regimens. The preferred first-line treatment is bortezomib combined with lenalidomide and dexamethasone. CAR T-cell therapies (e.g., Bristol Myers Squibb / Bluebird Bio’s Abecma, Johnson & Johnson Innovative Medicine / Legend Biotech’s Carvykti) and bispecific antibodies (e.g., Johnson & Johnson Innovative Medicine’s Tecvayli and Talvey, Pfizer’s Elrexfio) have expanded the options available for R/R disease. Therapies in late-phase development will, if approved, further fragment the treatment of multiple myeloma.

Questions answered

  • What is the size of the key drug-treatable populations? How will drug-treatment rates change over the 2023-2033 forecast period?
  • How will the current treatment landscape change over the forecast period, and what impact will generic entry have on the market?
  • Which emerging therapies are the most promising for multiple myeloma?
  • What factors are driving the growth of the multiple myeloma therapy market, and how will it evolve over the forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents


Related Market Assessment Reports

Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…